Login / Signup

Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.

Chulkue PakShinkyo YoonJae Lyun LeeTak YunInkeun Park
Published in: Current oncology reports (2024)
Research has delved into the genomic landscape of ACC, revealing potential targets for therapy. Despite the failure of inhibitors aimed at the insulin like growth factor 1(IGF-1) receptor, other approaches, including vascular endothelial growth factor receptor (VEFGR) tyrosine kinase inhibitors and immune checkpoint inhibitors, are being investigated. There are also ongoing trials of combination treatments such as lenvatinib with pembrolizumab and cabozantinib with atezolizumab. ACC remains a challenging malignancy with limited effective treatment options. Although EDP-M stands as the frontline treatment, the search for effective second-line therapies is ongoing. Targeted therapies and immunotherapies, especially in combination regimens, are demonstrating potential and are the subject of continued research. The evolving genomic landscape emphasizes the significance of targeted therapies and the need for further in-depth studies to solidify effective treatment regimens for ACC.
Keyphrases
  • vascular endothelial growth factor
  • stem cells
  • risk assessment
  • single cell
  • endothelial cells
  • combination therapy
  • cell proliferation
  • climate change
  • human health
  • pi k akt
  • growth hormone
  • high speed